POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
批准号:
3838223
负责人:
J E JANIK
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
clinical trials combination cancer therapy combination chemotherapy dosage double stranded RNA drug adverse effect enzyme induction /repression gene induction /repression human subject human therapy evaluation human tissue hypotension immunomodulators interferon inducers interferons methylcellulose neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy pharmacogenetics poly IC polylysine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Interferon induces the synthesis of a large number of gene products.
These products play a role in the antiviral and antiproliferative effects
of alpha interferon. Two of the induced gene products,
2',5'-oligoadenylate synthetase and the double-stranded inhibitor (DSI)
are induced by interferon but require double-stranded RNA to activate
them. The DSI plays a major role in inhibiting protein synthesis
initiation by phosphorylating the eukaryotic initiation factor 2 (elF-2)
on serine 51 of its alpha subunit.
This study combined administration of interferon alpha and Poly ICLC, a
form of double-stranded RNA, in order to determine the optimal dose level
of interferon for induction of the DSI and the optimal dose of Poly ICLC
for activation of the kinase. Three dose levels of interferon were
combined with one of four dose levels of Poly ICLC.
This study was designed to determine the toxicity of this combination and
the maximal tolerated dose. Dose-limiting toxicity was observed with the
combination of interferon 10 mu/m2 and Poly ICLC 0.03 mg/m2. Toxicity
consisted of prolonged hypotension requiring hospitalization for
intravenous fluid administration. Higher doses of Poly ICLC allowed
administration of interferon at the 10 mu/m2 dose level without this
toxicity. These results suggest that Poly ICLC may be more toxic at
lower doses or that higher doses of ICLC may reduce the toxicity of
interferon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:2464506
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
-
批准号:3874539
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH R-INTERFERON GAMMA
-
批准号:2464513
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I TRIAL OF TNF AND GM-CSF
-
批准号:3752523
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3752507
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A (R022-8181/002) IN HAIRY CELL LEUKEMIA
-
批准号:3752481
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3853339
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE 1 EVALUATION OF INTRATUMORAL INTERLEUKIN-1 ALPHA
-
批准号:3838227
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EVALUATION OF TOPOTECAN IN MELANOMA AND RENAL CELL CARCINOMA
-
批准号:3838238
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3752508
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163345
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE I EVALUATION OF A MODIFIED HEPATIC ARTERY INFUSION CATHETER
-
批准号:3838239
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3853335
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
RGM-CSF AND HIGH DOSE CARBOPLATIN THERAPY IN REFRACTORY OVARIAN CANCER
-
批准号:3853315
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE II EFFICACY STUDY OF ROFERON A IN HAIRY CELL LEUKEMIA
-
批准号:6163429
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE A IFN IN HAIRY CELL LEUKEMIA
-
批准号:3752475
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
PHASE IB TRIAL OF LEVAMISOLE ALONE AND IN COMBINATION WITH RIFN-GAMMA
-
批准号:3752495
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3752497
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
POLY ICLC AND ALPHA INTERFERON IN REFRACTORY MALIGNANCY
-
批准号:3874559
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
ALTERNATING 2'-DCF AND RECOMBINANT LEUKOCYTE INTERFERON ALPHA IN HCL
-
批准号:2464504
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:J E JANIK
-
依托单位:
海外基金